SUMMARY Plasma beta-thromboglobulin (BTG) was significantly elevated in the acute phase of 116 atherosclerotic thrombotic (p < 0-0001) and 36 cardioembolic (p < 0 005) infarcts but normal for 96 lacunes compared with controls. This elevation persisted into the 6th week after the acute event. Among atherosclerotic thrombotic infarcts, the acute beta-thromboglobulin level showed a tendency to correlate with infarct size on CT and predicted mortality at 6 weeks. These results suggest that platelet aggregation plays a primary role in the pathogenesis of atherothrombosis.
Platelet aggregation plays a significant role in normal haemostasis by sealing defects in the vessel wall. Pathological extension of platelet aggregation may, on the other hand, contribute to the development of occlusive vascular diseases. Recent studies have shown that antiplatelet agents are effective in improving the outcome of patients with cerebral' 2 or coronary arterial diseases.34 It seems likely that these antiplatelet agents would be most effective in those patients with increased platelet reactivity.
Platelet aggregation is associated with the release of a number of proteins including beta-thromboglobulin (BTG), which is a small protein stored in the oa-granules of platelets. Its function is unclear but it is possibly a "granule packing protein" stabilising the active constituents in the a-granules. Measurement of this platelet released material provides an index of platelet activation in vivo in atherosclerotic vascular disease and arterial thrombosis. 5 We hypothesise that the role played by platelet aggregation in cerebral infarct varies with the pathological nature of the ischaemic insult. Thus, atherosclerotic thrombotic infarction, a large-vessel disease that arises as a result of artery-to-artery embolism of platelet thrombi from the main carotid arteries or following thrombotic occlusion of a major cerebral artery, should be associated with significant platelet activation and hence an elevated BTG level. Lacunar infarction, on the other hand, is a smallvessel disease with lipohyalinosis of the penetrating end-arteries with in situ thrombosis.6 Platelet aggregation does not play any role in its pathogenesis and thus the BTG level should remain normal. Cardioembolic infarction arises from fibrin-platelet clots in the heart so that platelet activation may be expected to be present. We tested the hypothesis by measuring the BTG level in a consecutive series of ischaemic stroke patients. Patients Excluded were patients: (1) with disability from previous stroke or other neurological diseases; (2) taking aspirin or other antiplatelet agents; and (3) who could not be classified with certainty into any one of the four ischaemic subtypes.
Patient controls
Thirty five patients with various non-vascular neurological diseases served as patient controls; these included Parkinson's disease (13) , meningioma (7), glioma (6), alcoholic dementia (4), head injury (3) and Huntington's chorea (2).
Normal controls
The spouses of the stroke patients served as normal controls; none had a history of cardiovascular, cerebrovascular, or peripheral vascular diseases, although five subjects were known to have hypertension and one diabetes mellitus.
Plasma collection, preparation and assay of BTG Plasma collection and preparation for BTG assay were performed according to standard procedures.8 Venous blood (4 5 ml) was withdrawn from the antecubital vein using a gauge-21 needle without venous occlusion. The blood was immediately transferred into a pre-cooled plastic tube containing ETP (edetic acid EDTA 33 g/l, theophylline 1-8 g/l, prostaglandin E1 PGE1 1000 pg/1). The tube was inverted gently two to three times and then transferred to an ice-water bath for 15 minlutes. It was then centrifuged at 1200 g for 20 minutes at 4°C. The top 0 5 ml of platelet-poor plasma was collected and stored at -70°C until assay.
Plasma was collected as soon after admission as possible (acute BTG) and again at 6 weeks among the survivors (chronic BTG). The plasma concentration of BTG was measured by radioimmunoassay (RIA). The BTG RIA kit was purchased from the Radiochemical Centre, Amersham, England.
STATISTICAL METHODS
Statistical analysis was performed with the aid of the Statistical Package for the Social Sciences (SPSS-X). Data were analysed by Student's t-test or paired t-test where appropriate.
Results

Patients
The demographic characteristics of each stroke subtype and their distribution of risk factors are shown in the table. The stroke subtype was confirmed on CT in 255 (96.6%) patients and on necropsy in nine (3.4%) patients. Of the 255 patients who had CT confirmation, scanning was performed within the first 48 hours in 60 5%, between 3-7 days in 13-6%, in the second week in 15-2% and between 3-4 weeks in the remaining 10-7%.
BTG levels
Acute BTG was determined within the first 48 hours of onset of ictus in 67-4% of patients, between days 3-4 in 23-8% and between days 5-7 in the remaining 8-8%. The acute BTG levels are indicated in the table and fig 1. The mean (SD) value for the normal controls was 25 7 (6 9) ng/ml and that for the patient controls was 24-2 (7 2) ng/ml; there was no difference between these two groups of controls in spite of a significantly younger patient control population (52.5 (14.5) vs 64-8 (9 6) years, p < 0-0001).
The acute BTG (mean, SD) value was 28-9 (14-1) ng/ml for TIAs, 32-8 (16-4) ng/ml for AIs, 35 6 (17-6) ng/ml for Els and 23 5 (9-5) for LIs. Both Al and EI patients had significantly higher BTG levels than lacunes or controls. The mean BTG level for TIA patients lay between those for Al and LI patients, although not reaching any statistically significant difference. Acute BTG levels in lacunes were not significantly different from controls. Sex had no effect on BTG level. The mean (SD) value for the 36 male normal controls was 26-0 (6-7) ng/ml, and that for the 37 female normal controls was 25-3 (6&8) ng/ml (p > 0 1). Similarly, no difference was found between the male and female patients of each stroke subtype, although there were significantly more male LI and more female El patients.
There was a considerable degree of overlap (fig 1) repeated (fig 2) . The acute BTG level of patients still alive at 6 weeks was 30 5, 14-2 ng/ml, while that of patients who died was 39 9, 20A4 ng/ml (p <0-05).
The 6-week chronic BTG level in the 82 Al patients who had the test repeated was 30 9, 13-8 ng/ml. There was no significant difference from their acute BTG levels.
By contrast with Al, there was no significant difference in the acute BTG level between those EI patients who survived 6 weeks (26/36) and those who succumbed at 6 weeks (10/36), and there was no difference between the acute and 6-week BTG levels in the 22 EI patients who had a repeat BTG level taken (fig 3) .
Correlation between BTG and infarct size on CT TIAs: All 16 TIA patients had normal CT scans. AL: The infarct size on CT of the 116 Al patients ranged from 0-5 to 199-8 ml, with a median of 4-35 ml. By dividing into two subgroups according to the median infarct size (4-35 ml), the subgroup with larger infarcts (infarct size above median, n = 58, BTG 35-1, 16-7 ng/ml) had a higher acute BTG level than the subgroup with smaller infarcts (infarct size below median, n = 58, BTG 29-3, 14-1 ng/ml), with a significance level of p = 0-06 (fig 4) . Linear regression Beta-thromboglobulin in cerebral infaretion 
Discussion
Our study showed that in the acute phase after a stroke, the BTG level is significantly elevated among those with a cortical infarct, whether of atherosclerotic or cardioembolic origin, but the level was within the normal range for an age-matched population among those with a lacune. While other workers'0-13 have reported similar findings, our population is the largest cohort of patients with methodical timing of blood sampling to ensure meaningful results. The finding of elevated BTG levels in atherosclerotic thrombotic infarcts compared with that in lacunes is in keeping with the concept that the former represent large-vessel diseases in which platelet aggregation is important and that the latter represent small-vessel diseases with lipohyalinosis and in situ thrombosis without significant platelet activation. The fact that cardioembolic infarcts also have elevated BTG levels, signifying platelet activation, is not surprising. Pathologically, the hearts of these patients have mural clots consisting of fibrin-platelet mixtures. In addition, it had been shown in a prospective clinical study'4 that the addition of dipyridamole, an antiplatelet agent, to warfarin in patients who had prosthetic heart valve replacement reduced the incidence of embolic complications. This indicates that platelet activation does have a role to play in cardioembolic disease, although it may not be the most important pathogenic element.
Our results also indicated a considerable degree of overlap in the actual BTG value (fig 1) . The great majority of AI and LI patients have their BTG levels within mean 2 SD of the controls. Hence, a single BTG level in the acute phase of a stroke has little predictive value, and it is evident that BTG is a relatively insensitive indicator of the type of ischaemic injury.
It has been shown in experimental animals'5 that cerebral ischaemia can stimulate platelet aggregation. One may argue that the elevated BTG level in acute stroke is only an epiphenomenon and not causally related to the ischaemic event. However, the persistently elevated BTG levels at 6 weeks after ictus would suggest that platelet activation is a continuing process and that it is not related solely to an acute aggregating stimulus. In correlating acute BTG level and infarct size on CT, we showed that among atherosclerotic thrombotic infarcts, there was a tendency towards a higher BTG level to be associated with a larger infarct, although not actually reaching statistical significance. While these findings were consistent with the above observation of acute BTG predicting mortality at 6 weeks, the results had to be interpreted with caution because it is known that CT performed very early in the course of an extensive infarct may be deceptively unrevealing and we are unable, for logistic reasons, to perform CT at a standardised time after onset of ictus in every patient. Among lacunes, there was no difference in the acute BTG level in those whose CT scans were normal and those whose CT scans demonstrated a small lacunar lesion.
In conclusion, our observation of an elevated BTG level in cortical non-lacunar strokes suggests that antiplatelet therapy' 2 may be beneficial only in this subgroup of patients. Although the measurement of BTG provides a relatively simple way to identify the occurrence of platelet activation, we 
